ZNF423 rs746157: What Your Genotype Means
The rs746157 variant is a single nucleotide polymorphism located within the ZNF423 gene. It has been investigated in the context of breast cancer chemoprevention pharmacogenomics to understand how genetic differences may influence individual responses to preventive therapies.
What each genotype means
Baseline ZNF423 genotype
This genotype represents the common form of the ZNF423 variant. Research into this variant has explored its potential role in breast cancer chemoprevention pharmacogenomics, specifically regarding response to selective estrogen receptor modulators, but current evidence is not definitive. Please discuss any concerns regarding medication response or breast cancer risk management with your clinician or pharmacist.
This genotype is observed in the general population, though specific frequency data for this variant is not widely recorded.
Heterozygous ZNF423 variant
This genotype indicates you carry one copy of the variant allele. Studies have investigated whether this variant influences how individuals respond to preventive breast cancer therapies, but the findings are considered preliminary and not yet established for clinical use. Please discuss any concerns regarding medication response or breast cancer risk management with your clinician or pharmacist.
This genotype is observed in the general population, though specific frequency data for this variant is not widely recorded.
Homozygous ZNF423 variant
This genotype indicates you carry two copies of the variant allele. While this variant has been studied in the context of breast cancer chemoprevention pharmacogenomics, the evidence remains limited and does not currently support specific clinical decision-making. Please discuss any concerns regarding medication response or breast cancer risk management with your clinician or pharmacist.
This genotype is observed in the general population, though specific frequency data for this variant is not widely recorded.
Understanding the rs746157 Variant
The rs746157 variant is a specific genetic change, or single nucleotide polymorphism (SNP), located on chromosome 16. In the human genome, SNPs represent the most common type of genetic variation, where a single building block of DNA—a nucleotide—is replaced by another. For rs746157, the variation involves the substitution of a cytosine (C) for a thymine (T). This variant is situated within the ZNF423 gene, which provides instructions for making a protein that acts as a transcription factor. Transcription factors are essential proteins that bind to specific regions of DNA to help control the activity of other genes. By influencing gene expression, ZNF423 plays a role in various developmental processes and cellular functions, making it a subject of interest in studies exploring how genetic architecture contributes to complex health outcomes, including cancer susceptibility and treatment response.
The Role of ZNF423 in Research
The ZNF423 gene is primarily recognized for its function in regulating gene expression during development and cell differentiation. In the context of oncology, researchers have examined whether variations in this gene might influence the risk of developing breast cancer or affect how patients respond to chemopreventive agents. Chemoprevention refers to the use of medications to reduce the risk of developing cancer in individuals who are at higher risk. Studies, such as those utilizing deep sequencing and functional genomics, have looked at rs746157 to determine if it serves as a biomarker for drug efficacy or toxicity. While the evidence linking this specific variant to clinical outcomes is considered moderate, it remains a focus of pharmacogenomic research aimed at personalizing breast cancer prevention strategies. Understanding these associations is a complex task, as many genetic factors often work in concert to influence biological pathways.
Interpreting Genetic Associations
When researchers identify an association between a variant like rs746157 and a health outcome, it does not imply a direct cause-and-effect relationship. Instead, it suggests that the variant may be statistically linked to a specific trait or response within the populations studied. In pharmacogenomics, these findings are intended to help scientists identify potential pathways that could be targeted by future therapies. It is important to note that the evidence for rs746157 is currently limited, and findings may vary based on the ancestry of the study participants. Because breast cancer is a multifactorial condition influenced by a combination of genetics, environment, and lifestyle, a single SNP rarely provides a complete picture of an individual's health risk or drug response. Consequently, these research findings are not diagnostic and should not be used to make independent medical decisions regarding treatment or prevention.
Navigating Your Genetic Information
If you have received information about your rs746157 genotype, it is essential to view it within the context of current scientific understanding. This information is primarily intended for educational purposes and to facilitate discussions with healthcare professionals. You cannot use this data to predict your personal risk of breast cancer or to determine how you will respond to specific medications. If you are concerned about breast cancer risk or are currently taking chemopreventive medications, you should consult with your clinician or a qualified pharmacist. They can provide guidance based on your full medical history, clinical guidelines, and established diagnostic testing. Avoid making any changes to your prescribed medication regimen based on genetic reports without professional medical oversight. Genetic research is an evolving field, and as more data becomes available, the clinical significance of variants like rs746157 may be further clarified.
How common is this variant?
Specific population frequency data for rs746157 is not widely recorded in standard public databases, and its prevalence may vary significantly across different ancestral groups.
Frequently asked questions
What is the rs746157 variant?
The rs746157 variant is a single nucleotide polymorphism (SNP) located in the ZNF423 gene. It is a site in the DNA where individuals may have different nucleotides, which researchers study to understand potential links to breast cancer chemoprevention.
Does rs746157 cause breast cancer?
No, rs746157 is not considered a cause of breast cancer. It is a genetic marker that has been investigated in research studies for its potential association with how individuals respond to certain preventive medications.
Can I use my rs746157 result to change my medication?
No, you should never change your medication based on genetic test results. Always discuss your medications and any genetic information with your doctor or pharmacist before making changes to your treatment plan.
Where can I find more information about ZNF423?
You can find more information about the ZNF423 gene through resources like the NCBI Gene database or MedlinePlus Genetics. These sites provide detailed summaries of gene functions and their roles in human health.
Sources & further reading
Educational information only, last refreshed 9/19/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs746157?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29